[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-volunteers-hv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-volunteers-hv":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,52,82,101,126,154,175,210,233,263,285,308,334,353,373,402,425,451,477],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100649554","phase-1-a-first-in-human-study-of-ze66-0205-in-healthy-volunteers-100649554",false,"NCT07735728","A First-in-Human Study of ZE66-0205 in Healthy Volunteers","A Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZE66-0205 in Healthy Volunteers","Inclusion Criteria:\n\n* Written informed consent provided before any study-related activities; able to understand the nature, purpose, risks, and possible adverse effects of the study.\n* Male or female, 18 to 55 years of age, inclusive, at Screening.\n* Body mass index 18.0 to 32.0 kg\u002Fm², inclusive, and body weight no more than 100 kg at Screening.\n* Medically healthy in the opinion of the Investigator or delegate based on medical history and absence of clinically significant abnormalities, including: no clinically relevant physical-examination findings; systolic blood pressure 90 to 160 mmHg and diastolic blood pressure 50 to 95 mmHg after at least 5 minutes of rest; pulse rate 40 to 100 beats\u002Fminute after at least 5 minutes of rest; tympanic body temperature 35.5°C to 37.7°C; and electrocardiogram without clinically significant abnormalities, including QTcF less than 450 msec for males and less than 470 msec for females.\n* Female participants must be of non-childbearing potential (surgically sterilised at least 6 weeks before Screening or postmenopausal with confirmatory follicle-stimulating hormone level) or, if of childbearing potential, must have negative pregnancy tests at Screening and Day -1, agree not to become pregnant or donate ova until at least 30 days after the last dose, and use protocol-defined adequate contraception during this period unless exclusively in a same-sex relationship or abstinent as a committed lifestyle.\n* Male participants must agree not to donate sperm until at least 90 days after the last dose. When engaging in sexual intercourse with a female partner who could become pregnant, the participant must use a condom together with a protocol-defined highly effective method of contraception until at least 90 days after the last dose. When engaging in sexual intercourse with a female partner who is not of childbearing potential or with a same-sex partner, the participant must use a condom until at least 5 days after the last dose.\n* Suitable venous access for blood sampling.\n* Willing and able to comply with all study assessments, schedule requirements, and restrictions.\n\nExclusion Criteria:\n\n* History of anaphylaxis or another significant allergy that, in the opinion of the Investigator or delegate, could interfere with study participation.\n* History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease or disorder, including any clinically relevant acute illness within the previous 3 months.\n* Surgery or hospitalization within 3 months before Screening, or planned surgery during the study.\n* History of malignant disease within the previous 10 years, except surgically resected squamous-cell or basal-cell skin carcinoma with histopathologically confirmed clear margins.\n* Clinically relevant immunosuppression, including immunodeficiency conditions such as common variable hypogammaglobulinemia.\n* History of risk factors for torsade de pointes, including family history of long QT syndrome or sudden cardiac death, or a known arrhythmia.\n* Gastrointestinal, hepatic (including Gilbert syndrome), renal, or other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Gamma-glutamyl transferase, total bilirubin, alkaline phosphatase, aspartate aminotransferase, or alanine aminotransferase greater than 1.5 times the upper limit of normal, unless an isolated elevation is considered a normal variant by the Investigator or delegate and is not accompanied by clinical signs.\n* Estimated creatinine clearance below 60 mL\u002Fmin using the Cockcroft-Gault formula or serum creatinine greater than 1.5 times the upper limit of normal.\n* History of or positive Screening test for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibodies.\n* Positive urine drug-of-abuse test, carbon monoxide breath test, or alcohol breath test at Screening or Day -1.\n* Regular smoking of more than 5 cigarettes per week or equivalent, including tobacco, nicotine replacement therapy, e-cigarettes, or marijuana. Casual smokers may be eligible only if all protocol requirements are met.\n* Pregnant or breastfeeding female, or female planning to breastfeed from Screening until 3 months after the last dose or 5 half-lives, whichever is longer.\n* Unable to swallow oral medication.\n* Use of prescription medication, including oral contraceptives, within 14 days or 5 half-lives, whichever is longer, before the first dose; or use of over-the-counter medication within 7 days or 5 half-lives, whichever is longer, before the first dose, except protocol-permitted paracetamol.\n* Current infection requiring a systemically absorbed antibiotic, antifungal, antiparasitic, or antiviral medication within 10 days before the first dose.\n* Receipt of an inactivated vaccination within 14 days or a live vaccination within 30 days before the first dose, or planned vaccination during the study.\n* Use of systemic immunosuppressive or immunomodulating medication within 28 days or 5 half-lives, whichever is longer, before dosing or during the study.\n* Blood or plasma donation within 30 days before the first dose; loss of more than 500 mL of whole blood within 30 days before the first dose; or receipt of a blood transfusion within 1 year before the first dose.\n* Participation in a clinical study of an investigational drug or device within 30 days or 5 half-lives of the investigational drug, whichever is longer, before Screening.\n* Any other condition or prior therapy that, in the opinion of the Investigator or delegate, makes the participant unsuitable for the study, including inability to cooperate fully or likely noncompliance with study requirements.",true,"ALL","18 Years","55 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This first-in-human study will evaluate ZE66-0205 in healthy adults. The main purpose is to assess the safety and tolerability of single oral doses and, if evaluated, two doses given on Day 1. The study will also assess how ZE66-0205 is absorbed, distributed, and eliminated from the body and how it affects MALT1 levels in blood cells. Participants will be assigned by chance to receive ZE66-0205 or placebo in sequential ascending-dose cohorts.",[28],"Healthy Volunteers (HV)",[30,31,32,33,34,35,36,37,38],"ZE66-0205","MALT1","MALT1 degrader","proteolysis-targeting chimera","PROTAC","first-in-human","single ascending dose","pharmacokinetics","pharmacodynamics","NOT_YET_RECRUITING","2026-08-12",{"date":42,"type":43},"2026-08-14","ACTUAL",{"date":45,"type":22},"2026-08-15",{"date":47,"type":22},"2027-08-15",{"name":49,"class":50},"Eilean Therapeutics","INDUSTRY",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":51},"100650832","phase-1-frequency-dependent-effects-of-transcranial-photobiomodulation-with-same-peak-irradiance-on-cortical-excitability-and-fine-motor-performance-100650832","NCT07752602","Frequency-Dependent Effects of Transcranial Photobiomodulation With Same Peak Irradiance on Cortical Excitability and Fine Motor Performance","Frequency-Dependent Effects of Transcranial Photobiomodulation With Same Peak Irradiance on Cortical Excitability and Fine Motor Performance: A Randomized, Double-Blind, Sham-Controlled, Within-Subject Crossover Trial","Inclusion Criteria:\n\n* Voluntary Participation: Participants who are clear of their cognitive faculties, capable of understanding all experimental procedures, and who provide written informed consent prior to enrollment.\n* Neurologically and Psychiatrically Healthy Status: Individuals with no current or prior history of neurological, neurodevelopmental, or psychiatric conditions;\n* Age Range: Young adult volunteers aged between 18 and 35 years.\n\nExclusion Criteria:\n\n* Use of any continuous psychotropic medication within the past 12 months.\n* Any current psychiatric diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n* Diagnosis of any neurological disorder capable of altering cortical excitability (e.g., seizures\u002Fepilepsy, cerebrovascular accidents\u002Fstroke, brain tumors).\n* Any clinical, psychological, or social condition that, in the investigator's opinion, places the participant at an increased risk, compromises participant safety, or precludes full compliance and successful completion of the study protocol.\n* Presence of any intracranial devices or implants, including cochlear implants and aneurysm clips.\n* Severe or uncompensated systemic medical illness that could interfere with study participation or confound physiological outcomes.\n* Participation in any other interventional neuromodulation study within the preceding 6 months.","35 Years",{"count":61,"type":22},20,[25],"This study investigates the frequency-dependent neuromodulatory effects of transcranial photobiomodulation (tPBM) over the primary motor cortex (M1) on cortical excitability and fine motor performance in healthy young adults. Using a randomized, double-blind, sham-controlled, 5-arm crossover design, 20 healthy participants will undergo five experimental conditions separated by a mandatory 7-day washout period: Continuous Wave (CW), 10 Hz pulsed tPBM, 40 Hz pulsed tPBM, 100 Hz pulsed tPBM, and a Sham control. To isolate pulse frequency while holding peak intensity constant, all active interventions will utilize an identical peak irradiance, with pulsed modes operating at a 50% duty cycle (delivering 50% of the cumulative energy dose relative to CW). Primary outcomes include corticospinal excitability measured via single- and paired-pulse Transcranial Magnetic Stimulation (TMS), alongside fine motor speed and dexterity assessed via a computerized finger-tapping task.",[28,65,66],"Transcranial Photobiomodulation","Cortical Excitability",[68,69,70,71],"Finger Tapping Test","Healthy volunteers","Cortical excitability","Transcranial photobiomodulation","2026-08-03",{"date":74,"type":43},"2026-08-07",{"date":76,"type":22},"2027-01-01",{"date":78,"type":22},"2027-12-01",{"name":80,"class":81},"Hospital de Clinicas de Porto Alegre","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":51},"100647277","phase-1-frequency-dependent-effects-of-transcranial-photobiomodulation-on-cortical-excitability-100647277","NCT07707284","Frequency-Dependent Effects of Transcranial Photobiomodulation on Cortical Excitability","Frequency-Dependent Effects of Transcranial Photobiomodulation on Cortical Excitability and Fine Motor Performance: A Randomized, Double-Blind, Sham-Controlled, Crossover Trial",{"count":61,"type":22},[25],"This study aims to investigate the frequency-dependent effects of near-infrared (NIR) transcranial photobiomodulation (tPBM) on human cortical excitability and fine motor performance. A cohort of 20 healthy adult volunteers (aged 18-35 years) will participate in a randomized, double-blind, sham-controlled, single-center study utilizing a within-subject, five-arm crossover design. Each participant will undergo five distinct experimental conditions separated by a strict washout period: active Continuous Wave (CW) tPBM, active pulsed tPBM at three neural oscillation frequencies (10 Hz, 40 Hz, and 100 Hz), and an inactive Sham comparator. All interventions will be delivered using a clinical-grade near-infrared device.\n\nTo isolate the specific effects of pulse frequency from overall energy delivery, the total energy dose (cumulative Joules) and total exposure time will be held perfectly constant across all active arms. The pulsed conditions will keeps the average irradiance and cumulative fluence identical to the continuous wave mode. Cortical excitability will be assessed via single- and paired-pulse Transcranial Magnetic Stimulation (TMS) protocols over the primary motor cortex (M1). Fine motor performance will be quantified using a smartphone-based Finger Tapping Test (FTT). Safety and systemic parameters will be tracked using the Systematic Assessment for Treatment Emergent Events - Systematic Inquiry (SAFTEE-SI) and vital signs. The central hypothesis is that distinct modulation frequencies will differentially influence corticospinal excitability and motor execution, independent of the total energy delivered.",[28,65,66],[71,70,69,68],"2026-07-27",{"date":95,"type":43},"2026-07-28",{"date":97,"type":22},"2027-05",{"date":99,"type":22},"2028-07",{"name":80,"class":81},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":51},"100593609","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-lung-cancer-100593609","NCT07008664","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient at University of Maryland Baltimore Washington Medical Center\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at University of Maryland Baltimore Washington Medical Center\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English",{"count":108,"type":22},750,"OBSERVATIONAL","The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[112,113,28,114],"Lung Cancer","Lung Cancer Screening","Unhealthy Volunteers",[112,113,116,114],"Healthy Volunteers","RECRUITING",{"date":119,"type":43},"2026-07-29",{"date":121,"type":43},"2025-03-31",{"date":123,"type":22},"2032-04",{"name":125,"class":81},"University of Maryland, Baltimore",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":16,"sex":17,"minAge":133,"maxAge":18,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":51},"100647777","blood-flow-restriction-during-nordic-hamstring-exercise-in-elite-adolescent-athletes-100647777","NCT07715786","Blood Flow Restriction During Nordic Hamstring Exercise in Elite Adolescent Athletes","Comparison of Hamstring Muscle Oxygenation Responses During Nordic Hamstring Exercise and Blood Flow Restriction Nordic Hamstring Exercise in Elite Adolescent Athletes: A Crossover Experimental Study","Inclusion Criteria:\n\n* Elite adolescent athletes aged 14 to 18 years.\n* Licensed athletes with at least 3 years of regular sports participation.\n* Currently participating in a regular weekly training program.\n* Physically able to complete the Nordic Hamstring Exercise and study testing protocol.\n* Willing to participate in the study.\n* Able to provide written informed consent.\n* For participants younger than 18 years, written informed consent provided by a parent or legal guardian and assent provided by the participant.\n\nExclusion Criteria:\n\n* Hamstring injury within the previous 6 months.\n* Lower extremity surgery within the previous 6 months.\n* Current lower extremity pain or musculoskeletal injury that may interfere with exercise performance.\n* Cardiovascular, vascular, neurological, or other medical conditions that may contraindicate blood flow restriction exercise.\n* Presence of skin lesions or conditions preventing placement of the blood flow restriction cuff or MOXY sensor.\n* Inability to complete either exercise condition or follow the study protocol.","14 Years",{"count":135,"type":22},24,[137],"NA","This crossover experimental study aims to compare acute hamstring muscle oxygenation responses during Nordic Hamstring Exercise (NHE) and Blood Flow Restriction Nordic Hamstring Exercise (BFR-NHE) in elite adolescent athletes. Participants will complete both exercise conditions in a randomized order separated by a 7-day washout period. Muscle oxygen saturation will be assessed using near-infrared spectroscopy (MOXY), together with total hemoglobin responses, blood lactate concentration, perceived exertion, and exercise performance variables. The findings may improve understanding of the physiological effects of blood flow restriction during eccentric hamstring exercise in adolescent athletes.",[28],[141,142,143,144],"Nordic Hamstring Exercise","Blood Flow Restriction","Elite Adolescent Athletes","Muscle Oxygenation","2026-07-13",{"date":147,"type":43},"2026-07-20",{"date":149,"type":43},"2026-07-01",{"date":151,"type":22},"2027-08",{"name":153,"class":81},"Toros University",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":16,"sex":160,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100647397","phase-1-an-open-label-petct-imaging-study-to-evaluate-brain-serotonin-transporter-sert-occupancy-following-single-dose-administration-of-lg-0317-tablets-in-healthy-participants-100647397","NCT07708428","An Open-Label PET\u002FCT Imaging Study to Evaluate Brain Serotonin Transporter (SERT) Occupancy Following Single-Dose Administration of LG-0317 Tablets in Healthy Participants","Inclusion Criteria:\n\nHealthy male subjects age 18 to 45 years of age included.\n\n* Participant must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 19-28 kg\u002Fm2 inclusive.\n* The participant has normal results or abnormalities without clinical significance as judged by the investigator for vital signs, physical examination, laboratory tests (complete blood count, blood biochemistry, coagulation function, urinalysis), 12-lead electrocardiogram (ECG.\n* Fully understand the trial content, procedures, and possible adverse reactions; voluntarily participate and sign the informed consent form (ICF).\n* Able to communicate well with the study personnel, and understand and comply with the relevant requirements of the trial.\n\nExclusion Criteria:\n\n* 1\\) Allergic constitution, history of allergic diseases, or known allergy to the investigational product, its excipients, or related products.\n\n  2\\) History of current or prior neurological disorders, including but not limited to: history of head trauma or concussion; history of stroke or known cerebrovascular diseases (e.g., intracranial aneurysm, arteriovenous malformation); or other known structural abnormalities of the brain.\n\n  3\\) History of serious unstable diseases or related medical history affecting the hepatic, renal, gastrointestinal, endocrine, cardiovascular (including known aneurysmal vascular lesions), metabolic, hematological, respiratory, or autoimmune systems.\n\n  4\\) History of psychiatric disorders, substance abuse, or drug dependence. 5) Presence of epileptiform abnormalities (EAs) on screening electroencephalogram (EEG). (Screening EEG will include hyperventilation and intermittent photic stimulation as activation procedures.) 6) Personal history of epilepsy or family history of epilepsy in first-degree relatives (i.e., parents, siblings, or children).\n\n  7\\) Suicidal risk as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS); specifically, if the participant answers \"yes\" to Question 4 or 5 of the Suicidal Ideation section of the C-SSRS during screening and the most recent intent or plan occurred within the past 6 months; or answers \"yes\" to any question in the Suicidal Behavior section occurring within the past 2 years; or deemed at suicidal risk based on the investigator's clinical judgment.\n\n  8\\) Any relevant history of illness, surgery, or trauma within 3 months prior to the first dose that could affect safety or pharmacokinetics, or planned surgery during the study period.\n\n  9\\) Inability to swallow tablets. 10) Difficult venous access, intolerance to venipuncture\u002Findwelling catheters, or history of vasovagal syncope (fainting) related to needles\u002Fblood (needle-phobia or hemophobia).\n\n  11\\) Excessive consumption (\\>8 cups\u002Fday; 1 cup = 250 mL) of tea, coffee, or caffeinated beverages within 3 months prior to screening; or consumption of chocolate, caffeine-containing products, alcohol, grapefruit\u002Fgrapefruit juice, or xanthine-rich foods\u002Fbeverages within 48 hours prior to the first dose.\n\n  12\\) Alcohol consumption exceeding 21 standard units per week within 3 months prior to screening (1 standard unit contains 14 g of alcohol, e.g., 360 mL beer, 45 mL liquor at 40% alcohol, or 150 mL wine); or positive result on breath alcohol testing.\n\n  13\\) Smoking history ≥5 cigarettes per day within 3 months prior to screening. 14) Use of any prescription drugs, over-the-counter medications, herbal remedies, or dietary supplements within 14 days prior to the first dose.\n\n  15\\) Participation in another clinical trial involving investigational product within 3 months prior to the first dose.\n\n  16\\) Blood donation or significant blood loss (\\>400 mL), or receipt of blood transfusion within 3 months prior to the first dose.\n\n  17\\) Participation in a clinical study involving radiation exposure within the past 12 months, or receipt of significant diagnostic\u002Ftherapeutic radiation exposure for medical reasons within the past 12 months, leading to an estimated cumulative annual radiation dose exceeding safety limits (e.g., ≥10 mSv) based on ICRP recommendations.\n\n  18\\) Any contraindication to PET\u002FCT or MRI scanning, including but not limited to: presence of implanted metallic objects (e.g., cardiac pacemaker, metal prosthesis, implanted neurostimulator); claustrophobia; or body habitus\u002Fweight unsuitable for the PET\u002FCT or MRI scanner bore. Note: Contraindications identified during any prior MRI scan or the baseline MRI conducted prior to the screening PET\u002FCT scan also apply.\n\n  19\\) Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody (syphilis).\n\n  20\\) Use of illicit drugs within 3 months prior to screening or positive urine drug screen (including morphine, methamphetamine, methadone, phencyclidine \\[PCP\\], tetrahydrocannabinol carboxylic acid \\[THC-COOH\\], amphetamine, cocaine, barbiturates, benzodiazepines, ketamine, tricyclic antidepressants).\n\n  21\\) Plan to conceive, donate sperm, or unwillingness to use effective contraception during the study and for 3 months after the last dose.\n\n  22\\) Known photosensitive disorder or history of abnormal sensitivity to sunlight.\n\n  23\\) Affiliation with the study site staff, employment by the sponsor, or being an immediate family member of such personnel.\n\n  24\\) Any other condition that, in the investigator's opinion, makes the participant unsuitable for inclusion in the study.","MALE","45 Years",{"count":163,"type":22},12,[25],"The purpose of the study is to evaluate brain serotonin transporter (SERT) receptor occupancy (RO) following single oral doses of LG-0317 tablets in healthy male participants; and to explore the pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) relationship between LG-0317 plasma concentrations and SERT occupancy..",[28],{"date":168,"type":43},"2026-07-16",{"date":170,"type":22},"2026-07-24",{"date":172,"type":22},"2027-02-02",{"name":174,"class":81},"LinGang Laboratory",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":51},"100647342","phase-1-safety-of-topical-exosome-containing-liquid-in-healthy-volunteers-for-future-surgical-wound-use-100647342","NCT07707986","Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use","A Phase 1 Split-Site Pilot Study to Evaluate the Safety and Dermal Tolerability of Topical Exosome-Containing Liquid in Healthy Adult Volunteers Before Future Testing in Post-Melanoma-Excision Surgical Wounds","EV-MELSAFE","Inclusion Criteria:\n\n1. Healthy adult volunteers aged 18 to 55 years.\n2. Able and willing to provide written informed consent.\n3. No clinically significant abnormality based on medical history, physical examination, vital signs, and screening laboratory tests.\n4. Intact healthy skin at the planned application sites.\n5. Willingness to avoid applying other topical products, cosmetics, antiseptics, or irritant substances to the application sites during the study period.\n6. Willingness to avoid excessive sun exposure, sauna, swimming pool use, and mechanical irritation of the application sites during the study period.\n7. Willingness to comply with all study visits, topical application procedures, local skin assessments, skin photography, safety assessments, and follow-up.\n8. For women of childbearing potential, a negative pregnancy test before first application and willingness to use an acceptable method of contraception during the study period.\n\nExclusion Criteria:\n\n1. Any active skin disease, dermatitis, eczema, psoriasis, urticaria, acneiform eruption, skin infection, open wound, scar, tattoo, burn scar, pigmentation disorder, or clinically significant skin abnormality at the planned application sites.\n2. History of severe allergy, anaphylaxis, or hypersensitivity to topical liquids, dressings, biological products, exosome-containing products, or any component of the investigational product or vehicle liquid.\n3. Current acute illness, fever, or active infection.\n4. Known autoimmune disease, immunodeficiency, or current systemic immunosuppressive therapy.\n5. Use of systemic corticosteroids, immunomodulatory drugs, biological agents, or investigational products within 30 days before enrollment.\n6. Use of topical corticosteroids, topical immunomodulators, topical antibiotics, retinoids, keratolytic agents, or other medicated topical products on or near the planned application sites within 14 days before enrollment.\n7. Clinically significant hepatic, renal, cardiovascular, hematologic, endocrine, neurologic, psychiatric, or systemic disease that may increase risk or interfere with interpretation of study results.\n8. Known active malignancy or history of malignancy within the past 5 years.\n9. Positive screening test for clinically relevant transmissible infection, if required by the protocol.\n10. Pregnancy or breastfeeding.\n11. Positive pregnancy test at screening or before first application in women of childbearing potential.\n12. Participation in another interventional clinical trial within 30 days before enrollment.\n13. Blood donation or major blood loss within 30 days before enrollment, if laboratory safety monitoring is included in the protocol.\n14. Any condition that, in the investigator's judgment, would make participation unsafe or interfere with interpretation of study results.",{"count":184,"type":22},10,[25],"This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers. The investigational liquid will be applied to a small defined area of intact skin. A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control. The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration. No melanoma lesion, surgical wound, burn wound, or artificial skin wound will be induced in participants in this Phase 1 safety study.",[28,188],"Skin Irritation",[190,191,192,193,194,195,196,35,197,198,199,200,201],"exosomes","extracellular vesicles","topical exosome-containing liquid","healthy volunteers","skin tolerability","skin irritation","phase 1","post-melanoma-excision wound","surgical wound repair","postoperative wound healing","Dermal Tolerability","dermal safety","2026-07-12",{"date":168,"type":43},{"date":205,"type":22},"2026-09",{"date":207,"type":22},"2027-01",{"name":209,"class":81},"West Kazakhstan Marat Ospanov Medical University",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":51},"100644715","phase-1-a-study-to-assess-the-absolute-bioavailability-and-how-adimanebart-sc-moves-through-the-body-in-healthy-adult-participants-100644715","NCT07673601","A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants","A Phase 1, Open-Label, Randomized, Single Dose, Parallel-Group Study to Assess the Absolute Bioavailability and Evaluate the Effect of Body Weight on the Pharmacokinetics of Adimanebart SC in Healthy Adult Participants","Inclusion Criteria:\n\n* Is at least the local legal age of consent and aged 18 to 65 years, inclusive, when signing the ICF.\n* Has a body weight between 60 and 100 kg and a BMI between 18.5 and 30 kg\u002Fm2, inclusive, at screening and on day -1 for part 1 and part 3, or has a body weight \\\u003C60 kg or between 100 and 130 kg and a BMI between 18.5 and 38.0 kg\u002Fm2, inclusive, at screening and on day -1 for part 2.\n* Discontinues and refrains from using all medications, including nonprescription and prescription medications, for ≥2 weeks before IMP administration, except for hormonal contraceptives and hormone replacement therapy in female participants. The occasional use of acetaminophen or ibuprofen is allowed.\n\nExclusion Criteria:\n\n* Has any current or past clinically meaningful medical or psychiatric condition, including severe hypersensitivity reactions to drugs and\u002For food that, in the investigator's opinion, would confound the study results or put the participant at undue risk.\n* Previously participated in an adimanebart clinical study and received at least 1 dose of IMP.\n* Is currently participating in another interventional clinical study, or has received an IMP in another clinical study within 12 weeks or 5 half-lives (whichever is longer) before screening.","65 Years",{"count":219,"type":22},52,[25],"This study aims to find out how much adimanebart gets into the blood circulation of healthy adults. Researchers will measure the amount of adimanebart in blood over time to learn how it moves through the body. The drug's safety will also be assessed.\n\nThe participants will be assigned to one of 3 parts of the study: part 1 investigates the absolute bioavailability; part 2 investigates the effect of different body weights on adimanebart in blood after subcutaneous (SC) dosing; part 3 investigates formulation adaptations.\n\nParticipants will be in the study for approximately up to 24 weeks.",[28,223],"Healthy Volunteer","2026-06-23",{"date":226,"type":43},"2026-06-29",{"date":228,"type":43},"2026-06-12",{"date":230,"type":22},"2026-12",{"name":232,"class":50},"argenx",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":51},"100641715","electrical-nerve-stimulation-during-sleep-for-memory-consolidation-100641715","NCT07658274","Electrical Nerve Stimulation During Sleep for Memory Consolidation","Effects of 2 Hz and 120 Hz Transcutaneous Electrical Nerve Stimulation During Sleep on Procedural Memory and Working Memory: A Randomized, Sham-Controlled, Crossover Study","Inclusion Criteria:\n\n1. Healthy young adults (e.g., college students), aged generally between 18 and 30 years.\n2. Right-handed.\n3. Body Mass Index (BMI) ≤ 30 kg\u002Fm\\^2.\n4. Capable of fully comprehending the experimental procedures and voluntarily signing the informed consent form.\n\nExclusion Criteria:\n\n1. History or current presence of neurological disorders, psychiatric disorders, or brain damage.\n2. History or current presence of cardiovascular diseases (e.g., arrhythmias or abnormal nocturnal heart rate).\n3. Presence of depressive or anxiety symptoms (assessed by Patient Health Questionnaire-9 \\[PHQ-9\\] score \\> 9, or Generalized Anxiety Disorder-7 \\[GAD-7\\] score \\> 9).\n4. Presence of sleep disturbances or poor sleep quality (assessed by Insomnia Severity Index \\[ISI\\] score \\> 8, or Pittsburgh Sleep Quality Index \\[PSQI\\] score \\> 10).\n5. Any medication use within the past six months that could affect stress responses, cognitive abilities, or sleep architecture.\n6. History of smoking or alcohol abuse.\n7. Known skin allergies to conductive paste, medical tape, or silicone electrodes.\n8. Female participants who are in their menstrual period during the scheduled experimental sessions (sessions must be strategically scheduled to avoid this period).\n9. Inability or refusal to abstain from caffeine, tea, and alcohol for at least 24 hours prior to and during the experimental sessions.",{"count":241,"type":22},30,[137],"The purpose of this study is to investigate the effects of transcutaneous electrical nerve stimulation (eTNS) applied during sleep on memory consolidation and brain-body physiological coupling. Healthy college students will participate in four overnight sleep sessions in a standard sleep laboratory.\n\nBefore going to sleep, participants will learn and complete two cognitive tasks: a motor sequence tapping task to assess procedural memory, and an N-back task to assess working memory. During the night, participants will receive either 2 Hz eTNS, 120 Hz eTNS, or a sham (placebo) stimulation on their forehead in a randomized order. Throughout the night, researchers will record their sleep using polysomnography (PSG), along with continuous monitoring of heart rate (ECG) and breathing (respiration). Upon waking the next morning, participants will be re-tested on both memory tasks.\n\nThe primary objective is to determine whether eTNS during sleep can improve behavioral performance on procedural and working memory tasks overnight. Secondary objectives include analyzing the stimulation's effects on specific sleep brain wave patterns (such as slow oscillations and sleep spindles) and exploring the coupling mechanisms between brain activity, heart rhythms (Heartbeat Evoked Potentials), and respiration during sleep.",[28],[246,247,248,249,250,251,252,253],"Transcutaneous Electrical Nerve Stimulation","eTNS","Procedural Memory","Working Memory","Slow Oscillations","Sleep Spindles","Heartbeat Evoked Potentials","Polysomnography","2026-06-21",{"date":256,"type":43},"2026-06-24",{"date":258,"type":22},"2026-06-16",{"date":260,"type":22},"2026-07-31",{"name":262,"class":81},"Xidian University",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":51},"100633381","phase-1-a-single-dose-phase-1-study-of-jade101-in-healthy-japanese-and-chinese-participants-100633381","NCT07525947","A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants","A Phase 1, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Japanese and Chinese Participants.","Inclusion Criteria:\n\n1. Healthy male or female participants 18-55 years of age, inclusive\n2. First-generation Japanese or Chinese participants born in Japan\u002FChina\n3. A body weight between 40-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg\u002Fm2 (all inclusive) at screening\n4. Willing and able to comply with the study site stay, scheduled visits, and study procedures\n5. Willing and able to comply with contraceptive and lifestyle requirements from admission through the end of the study\n\nExclusion Criteria:\n\n1. Harmful alcohol use\n2. Smoking\u002Fvaping or heavy tobacco use within 2 years prior to screening\n3. Known history of abuse of illicit drugs\n4. Nursing, lactating or pregnant, or who have plans to become pregnant during the study\n5. Known history of clinically significant disease\n6. Known history of immunodeficiency disorder\n7. History of clinically significant allergic reactions or hypersensitivity",{"count":271,"type":22},40,[25],"This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.",[28],[276],"JADE101","2026-06-02",{"date":279,"type":43},"2026-06-04",{"date":281,"type":43},"2026-05-01",{"date":97,"type":22},{"name":284,"class":50},"Jade Biosciences, Inc.",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":51},"100640716","phase-1-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-kr25102-in-healthy-volunteers-100640716","NCT07618156","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers","A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Single and Multiple Ascending Intravenous Doses of KR25102 for Injection in Healthy Adult Chinese Participants","Inclusion Criteria:\n\n1. Male and female participants aged between 18 and 55 years inclusive (as of the time of signing the informed consent form);\n2. Male participants with body weight ≥ 50 kg and female participants with body weight ≥ 45 kg, with a body mass index (BMI) ranging from 19 to 26 kg\u002Fm² (inclusive of boundary values);\n3. Participants and their partners have no plans for conception, sperm donation or oocyte donation from signing the informed consent form until 2 months after the last dose of study drug, and are willing to adopt highly effective contraceptive measures;\n4. Female participants: not pregnant or breastfeeding; female participants of child-bearing potential must have negative serum pregnancy test results at screening and baseline visits;\n5. For groups requiring pain testing: willing to undergo pain tests and pass training; with no wounds or skin diseases on the skin at the pain-stimulated site;\n6. Participants fully understand the purpose, requirements and potential risks of this trial, are willing to strictly comply with all trial requirements, voluntarily participate in the clinical trial and sign the written informed consent form.\n\nExclusion Criteria:\n\n1. Subjects with previous or current clinical acute or chronic diseases including but not limited to cardiovascular, endocrine-metabolic, neuropsychiatric, digestive, respiratory, hematopoietic-lymphoid, immune, urinary, musculoskeletal diseases and malignant tumors, who are judged unsuitable for enrollment by the investigator;\n2. Subjects with personal or family history of hereditary angioedema;\n3. Subjects who have undergone major surgery within 6 months prior to screening, or plan to receive surgical operations during the trial;\n4. Subjects who have taken any medicines or health supplements (including Chinese herbal medicines) within 14 days before dosing; or those who are known to require other drug treatments during the trial at screening.\n5. Subjects who have used any hepatic enzyme inhibitors\u002Finducers within 1 month before dosing (inhibitors such as itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin or nefazodone; inducers such as carbamazepine, phenytoin, phenobarbital, St. John's wort, etc.).\n6. Subjects who have participated in any clinical trials with investigational drugs\u002Fdevices within 3 months prior to screening, or plan to participate in other clinical trials during the study.\n7. Subjects with a history of drug abuse or positive results in drug abuse screening;\n8. Subjects with clinically significant abnormal physical examination results at screening or baseline as judged by the investigator;\n9. Subjects with positive screening results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody or treponema pallidum antibody;\n10. Subjects with cardiac diseases including but not limited to congenital long QT syndrome, torsades de pointes or risk factors for torsades de pointes (e.g., cardiac insufficiency, family history of long QT syndrome), those currently receiving Class IA anti-arrhythmic drugs (e.g., quinidine or procainamide), Class III anti-arrhythmic drugs (e.g., amiodarone or sotalol) or other drugs known to affect QT interval, or those with Fridericia-corrected QT interval (QTcF) ≥ 450 ms (male), QTcF ≥ 460 ms (female), PR interval \\> 200 ms or QRS interval ≥ 120 ms at screening;\n11. Subjects who fail pain test training as judged by the investigator (only applicable to groups requiring pain testing).",{"count":293,"type":22},83,[25],"Phase 1 Single Ascending Doses(SAD): Six cohorts of 53 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo.\n\nPhase 1 Multiple Ascending Doses(MAD): Three cohorts of 30 HVs will receive multiple IV bolus injections of study drug or placebo every day. After 7 days of continuous administration, the safety, tolerance and Pharmacokinetic\u002FPharmacodynamic characteristics of multiple administrations were evaluated.",[28],[298],"KR25102, Pharmacokinetics, Safety","2026-05-25",{"date":301,"type":43},"2026-06-01",{"date":303,"type":22},"2026-06",{"date":305,"type":22},"2027-03",{"name":307,"class":50},"Jiangxi Kvvit Pharmaceutical Co., Ltd.",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":16,"sex":17,"minAge":314,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":322,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":332,"locationsCount":4},"100638008","assessment-of-signal-consistency-between-needle-and-surface-electrodes-in-tibialis-anteror-muscle-a-pilot-validaton-study-100638008","NCT07579923","Assessment Of Signal Consistency Between Needle And Surface Electrodes In Tibialis Anterıor Muscle: A Pilot Validaton Study","Inclusion Criteria:\n\n* 20-60 years old\n* Female and male\n\nExclusion Criteria:\n\n* muscle disease\n* stroke\n* spinal cord injury\n* history of disc herniation surgery,\n* polyneuropathy-causing diseases (DM, thyroid, etc.)\n* professional athletes","20 Years","60 Years",{"count":241,"type":22},[137],"The aim of this study is to evaluate whether surface electrodes can record physiological muscle activity as accurately as the gold-standard needle electrodes in the tibialis anterior muscle using a diagnostic EMG device The aim of this pilot study is to investigate whether muscle activation data, similar to surface electromyography (SEMG), can be obtained by adjusting the measurement and recording parameters of standard Electroneuromyography (EMG) devices used routinely for diagnostic purposes. Although SEMG is considered the gold standard for the objective assessment of muscle activation, its clinical use in our country is limited due to the high cost of specialized hardware and software. In contrast, diagnostic EMG devices are widely available in many healthcare institutions.\n\nThe research will be conducted on 30 healthy volunteers between the ages of 20 and 60. Participants will undergo lower extremity nerve conduction studies, reflex response measurements, and muscle activation assessments during voluntary isometric contractions of the m. tibialis anterior. Muscle activation will be recorded using the diagnostic EMG device via surface (adhesive and Ag\u002FAgCl coated) electrodes and needle electrodes. The acquired EMG signals will be analyzed in terms of RMS (Root Mean Square), amplitude, and frequency parameters.\n\nThe procedures performed within the scope of this study are standard practices carried out during routine EMG examinations. The only additional procedure specific to this research is the repetition of muscle activation measurements using different electrode systems. There is no invasive procedure involved in the surface electrode applications, and the needle electrode application will be performed exactly as it is in routine EMG tests. No serious risks are anticipated; rarely, mild pain, redness, or minor bleeding at the needle insertion site may occur.\n\nThrough this study, diagnostic EMG devices could be utilized more effectively in rehabilitation and treatment monitoring. It is intended to contribute to the reduction of invasive procedures and to establish a scientific foundation for clinical applications regarding the objective evaluation of muscle activation.",[28,320,321],"Muscle Activation","Electromyography",[323,324,325],"Surface Electrodes","Needle Electrode","Motor Unit Action Potential (MUAP)","2026-05-16",{"date":328,"type":43},"2026-05-20",{"date":330,"type":22},"2026-04-24",{"date":149,"type":22},{"name":333,"class":81},"Romatem Bursa Hospital",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":51},"100627523","phase-1-phase-i-study-of-hxn6005-in-adult-healthy-participants-100627523","NCT07449741","Phase I Study of HXN6005 in Adult Healthy Participants","A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamics of HXN6005 in Healthy Participants","Inclusion Criteria:\n\n1. Participants must sign an Institutional Review Board (IRB) approved informed consent form before any study specific procedure.\n2. Male and female participants aged between 18 to 55 years, inclusive.\n3. Participants must have a body mass index between 18 to 35 kg\u002Fm2, inclusive.\n4. Healthy participants, in the opinion of the Investigator and as determined by medical history, with normal or clinically acceptable physical examination, clinical laboratory tests and ECG results at Screening and before randomization.\n5. Female participants must be postmenopausal, surgically sterile, or, if of childbearing potential, agree to use highly effective contraception combined with a condom from screening until 180 days post-dose, and refrain from egg donation or in vitro fertilization during this period.\n6. Male participants, with their female partner of childbearing potential, agree to use a condom as well as highly effective contraception, and refrain from sperm donation and in vitro fertilization until 180 days after the dosing of the study drug.\n7. Participants must be willing to understand and comply with all research procedures and restrictions, and able to communicate effectively with researchers.\n\nExclusion Criteria:\n\n1. Females who are pregnant, planning to become pregnant, or lactating during the trial;\n2. History of febrile illness or evidence of any active or suspected infection within 30 days before randomization;\n3. Participant at risk for tuberculosis;\n4. History of malignancy within 5 years before randomization, except for non-melanoma skin cancers (e.g., basal cell carcinoma, squamous cell carcinoma) that have been successfully treated\u002Fexcised for more than 12 months;\n5. Have known type I\u002FII diabetes;\n6. Positive for human immunodeficiency virus antibodies, syphilis antibodies, hepatitis B surface antigen, or hepatitis C antibodies;\n7. Positive for drugs use before randomization;\n8. Have used nicotine or tobacco containing products within 3 months prior to dosing, or unwilling to abstain from the use of tobacco or nicotine containing products during confinement in the CRU;\n9. Have a history of alcohol abuse (alcohol consumption in excess of 14 units per week (1 unit contains 14g alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) in the past one year before randomization, or unwilling to abstain from alcohol for 48 hours prior to admission to the CRU;\n10. Have received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 30 days or 5 half-lives before randomization, or plan to receive another experimental agent during the trial;\n11. Known exposure to any type of antibody or anti-TSLP therapy within 5 half-lives before randomization;\n12. Have donated blood (excluding plasma donations) of approximately 1 pint (500 mL) or more within 30 days before randomization, or those who plan to donate blood during the trial or within 30 days after the end of the study;\n13. Use of prescription or over-the-counter drugs or dietary or herbal supplements within 7 days or 5 half-lives (whichever is longer) before randomization;\n14. Recent exposure to live vaccines within 30 days, or non-live vaccines (including mRNA COVID\u002Fflu) within 2 weeks before randomization, or plan to receive vaccines during the trial;\n15. Participants with herpes zoster reactivation or cytomegalovirus that resolved within 60 days before randomization;\n16. Have clinically significant interventional therapies (surgery, paracentesis, etc.) within 6 months before randomization, or plan to have any surgeries during the trial;\n17. History of clinically significant hypersensitivity reactions to biologic agents, therapeutic proteins, or to specific excipients relevant to the study drug formulation.\n18. Have any other conditions that would, in the opinion of the investigator, put the participants at increased risk for participation in this trial.",{"count":21,"type":22},[25],"The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants.\n\nResearchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug).\n\nParticipants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.",[28],"2026-04-21",{"date":330,"type":43},{"date":348,"type":22},"2026-04-27",{"date":350,"type":22},"2027-03-13",{"name":352,"class":50},"Helixon Biotechnology (Suzhou) Co., Ltd",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":361,"conditions":362,"keywords":365,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":370,"leadSponsor":372,"locationsCount":51},"100621759","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-breast-cancer-100621759","NCT07374796","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient of UMMS\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at UMMS\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English",{"count":360,"type":22},450,"The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[363,28,114,364],"Breast Cancer (Locally Advanced or Metastatic)","Breast Cancer Screening",[366,364,116,114],"Breast Cancer",{"date":368,"type":43},"2026-04-22",{"date":301,"type":22},{"date":371,"type":22},"2032-07",{"name":125,"class":81},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":51},"100635279","phase-1-drug-drug-interaction-study-of-mdr-001-with-rifampin-and-itraconazole-in-healthy-adult-participants-100635279","NCT07550621","Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants","A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of MDR-001 and the Effect of Itraconazole on the Pharmacokinetics of MDR-001 in Healthy Adult Study Participants","Inclusion Criteria:\n\n* Voluntary participation and signed informed consent before any study procedures, with full understanding of the study content, procedures, and potential adverse reactions.\n* Healthy Chinese adult males or females aged 18 to 55 years (inclusive).\n* Body weight ≥50 kg for males and ≥45 kg for females, and body mass index (BMI) between 18 and 28 kg\u002Fm² (inclusive).\n* Judged by the investigator to be in good health, with medical history, laboratory tests, physical examination, vital signs, and ECG results being normal or abnormal without clinical significance.\n* Participants and their partners must have no pregnancy plan and agree to use effective non-drug contraceptive measures (e.g., condoms, non-medicated intrauterine devices) from 2 weeks before screening until 6 months after the end of the study, unless permanent sterilization has been performed (e.g., bilateral tubal ligation, vasectomy).\n* Willing to comply with the visit schedule, study treatment, laboratory tests, and other study-related procedures and requirements as specified in the protocol.\n\nExclusion Criteria:\n\n* Average daily smoking \\>5 cigarettes within 3 months before dosing.\n* History of headaches (e.g., migraine, tension-type headache).\n* Allergic constitution (multiple drug or food allergies) or intolerance\u002Fallergy to the active ingredient or excipients of the study drugs.\n* History of alcohol abuse (≥14 units of alcohol per week; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine).\n* History of drug abuse or use of illicit drugs within 5 years before dosing.\n* Blood donation or significant blood loss (≥400 mL) within 3 months before dosing, or planned blood donation during the study.\n* Any disease that increases bleeding risk, such as acute gastritis or gastric\u002Fduodenal ulcer.\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or genetic conditions predisposing to MTC.\n* History of pancreatitis or symptomatic gallbladder disease.\n* Serum calcitonin \\> upper limit of normal (ULN) at screening.\n* Dysphagia, or gastrointestinal disorders affecting absorption (e.g., diarrhea, vomiting, inflammatory bowel disease, active ulcer), or history of gastrointestinal surgery leading to malabsorption, or long-term use of drugs affecting gastrointestinal motility (e.g., bariatric surgery such as gastric banding).\n* Special dietary requirements and unable to accept standardized meals.\n* Surgery within 3 months before dosing, or planned surgery during the study, or surgery that affects drug absorption, distribution, metabolism, or excretion.\n* Received live attenuated vaccine within 1 month before dosing, or planned vaccination during the study.\n* Use of any prescription drug, over-the-counter drug, vitamin product, or herbal medicine within 14 days before dosing.\n* Significant changes in diet or exercise habits within 3 months before dosing.\n* Use of CYP3A4 inhibitors, CYP3A4 inducers, or P-gp inhibitors within 14 days before the first dose, or planned use during the study.\n* Participation in another clinical trial or receipt of an investigational drug within 3 months before dosing (unless the participant withdrew before treatment\u002Frandomization).\n* ECG abnormalities with clinical significance at screening; QTcF \\>450 msec (males) or \\>470 msec (females) by Fridericia's correction.\n* Pregnant, lactating, or positive pregnancy test in females of childbearing potential.\n* Clinically significant laboratory abnormalities, or clinically significant diseases within 12 months before dosing (respiratory, circulatory, digestive, endocrine, rheumatic\u002Fimmune, nervous, hematologic, or psychiatric disorders) that make the participant unsuitable for the study.\n* Positive screening for hepatitis B surface antigen, hepatitis C antibody\u002Fcore antigen, HIV antibody, or syphilis antibody.\n* Acute illness or concomitant medication between screening and first dose.\n* Positive alcohol breath test or urine drug screen.\n* Any other condition judged by the investigator as unsuitable for participation.",{"count":381,"type":22},28,[25],"A Phase I, open-label, fixed-sequence, two-part drug-drug interaction study in healthy Chinese adults to evaluate the effect of multiple-dose rifampin (Part A) or itraconazole (Part B) on the single-dose pharmacokinetics of MDR-001, an oral GLP-1 receptor agonist.",[28],[386,387,388,389,390,391,392,393,69],"MDR-001","GLP-1 receptor agonist","Drug-drug interaction (DDI)","Rifampin","Itraconazole","CYP3A4 inducer","CYP3A4 inhibitor","Pharmacokinetics (PK)","2026-04-19",{"date":330,"type":43},{"date":397,"type":22},"2026-05-06",{"date":399,"type":22},"2026-06-08",{"name":401,"class":50},"MindRank AI Ltd",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":51},"100616796","phase-1-research-into-the-safety-of-a-new-agent-vt-5006-in-people-with-and-without-parkinsons-disease-100616796","NCT07310264","Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease","A Phase I, Randomized, Single Ascending Dose, Multiple Ascending Dose, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AX-5006 (Aka VT-5006) in Healthy Participants and Participants With Parkinson's Disease.","Parts A and B enroll healthy volunteers; only key entry criteria for Part C are described below.\n\nInclusion Criteria:\n\n* Diagnosed with PD confirmed by a neurologist within a maximum of 10 years (based of year of diagnosis) prior to screening\n* Has current or history of GI motility dysfunction or persistent constipation\n* Score of \\\u003C 3 on the Modified Hoehn and Yahr Scale\n* Is able to swallow multiple and large capsules without assistance or difficulty, in the opinion of the investigator\n* Participants should be on a stable regimen of any prescribed (except levodopa\u002Fcarbidopa, levodopa\u002Fbenserazide or anticholinergic agents) or over-the-counter medications or supplements for at least 60 days prior to enrolment in the study. Participants should not change the dosage or frequency of these medications or supplements while in the study. If changes to medications or supplements are contemplated during the study, the Investigator should be contacted prior to any change.\n* Has suitable venous access for blood sampling\n\nExclusion Criteria:\n\n* Has a known allergy or hypersensitivity to any component of the formulation of VT-5006 or matching placebo, or history of severe allergy or anaphylaxis to a drug, food, or other exposure\n* Participants taking levodopa\u002Fcarbidopa or levodopa\u002Fbenserazide must remain on a stable dose and regimen from at least 21 days prior to Day 1 visit to end of study (EOS) visit. Other treatments for PD symptoms may be allowed at the discretion of the medical monitor\n* Has any clinically significant arrhythmia(s) on ECG; specifically, the participant's corrected QT interval (QTcf) (Fridericia's correction) is \\>450 ms for males or \\>470 ms for females\n* Has clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy participants\n* Has any of the following test results: a serum total bilirubin value \\>1.5 x upper limit of normal (ULN); a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value 2x ULN. As an exception, participants that present with elevated bilirubin in the absence of elevations in ALT or AST that fits the pattern of Gilbert's syndrome may be enrolled after discussion with the medical monitor if their conjugated bilirubin is not or slightly elevated and the level is considered to be not clinically significant.\n* Any history of lumbar surgery for any reason (e.g. herniated disc) that in the opinion of the Investigator would interfere with or pose risks to a lumbar puncture procedure\n* Other contraindications to having a lumbar puncture","80 Years",{"count":411,"type":22},84,[25],"This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD). The goal of this clinical trial is to learn if VT-5006 is safe and tolerable in healthy volunteers and in participants with PD. It has three Parts (A, B, and C).\n\nPart A: Healthy volunteers aged 18-54 will attend a screening visit, take a single dose of VT-5006 or matching placebo after an overnight fast, stay in the clinic for three nights, and complete a follow-up visit. One group of participants in Part A will be asked to return to the clinic after approximately two weeks, take a single dose of VT-5006 or matching placebo after consuming a high-fat meal and stay in the clinic for another three nights.\n\nPart B: Healthy volunteers aged 18-54 will attend a screening visit, take one dose of VT-5006 or matching placebo each day for seven days after fasting overnight, stay in the clinic for 10 nights, and complete a follow up visit.\n\nPart C: Participants with PD aged 40-80 will attend a screening visit, take one dose of VT-5006 (high dose), VT-5006 (low dose), or matching placebo each day for 28 days, complete two overnight stays in the clinic, attend three clinic visits, one phone call and a follow up visit.",[28,415],"Parkinson's Disease (PD)","2026-03-17",{"date":418,"type":43},"2026-03-20",{"date":420,"type":43},"2025-10-30",{"date":422,"type":22},"2026-09-28",{"name":424,"class":50},"Vertero Therapeutics",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":217,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":448,"locationsCount":450},"100618050","effects-of-a-sleep-education-program-on-the-health-status-of-healthcare-workers-working-12-hour-alternating-day-night-shifts-100618050","NCT07326579","Effects of a Sleep Education Program on the Health Status of Healthcare Workers Working 12-hour Alternating Day-night Shifts","Effects of a Sleep Education Program Conducted by Occupational Health Nurse on the Health Status of Healthcare Workers Working 12-hour Alternating Day-night Shifts: a Multicentre Randomised Controlled Trial","SLEEPMORE","Inclusion Criteria:\n\n* Being a paramedical caregiverr (nurse or care assistant)\n* Working 12-hour shifts (day\u002Fnight)\n* Working at least 80% of a full-time equivalent post\n* Staff employed at a hospital listed among the investigating centers\n* Being affiliated or entitled under a social security scheme\n* Having received informed information about the study and have co- signed, with the investigator, a consent to participate in the study\n\nExclusion Criteria:\n\n* Nursing staff and nursing assistants who have been exposed for more than six months to alternating 12-hour shifts or atypical working hours (two eight-hour shifts, three eight-hour shifts or night shifts) during their professional career\n* Nursing staff and nursing assistants with a history of mental illness or who are taking medication that affects alertness (psychotropic drugs)\n* Pregnant or breastfeeding women\n* Nursing staff or nursing assistants with sleep apnea syndrome, central hypersomnolence disorders, severe parasomnias, severe untreated restless legs syndrome\n* Individuals with children under the age of 1 in the household\n* Trans meridian travel (\\>2 time zones) during the month prior to the study",{"count":434,"type":22},160,[137],"In a context of seeking a better balance between personal and professional life and labor shortages, the use of 12-hour alternating day-night shifts has become more common in work organizations, particularly in healthcare facilities. This work pattern combines exposure to alternating day and night shifts with long working hours, raising questions about its effects on health, particularly sleep quality and cardiovascular risk. Staff working alternating day\u002Fnight or night shifts are at risk of cardiovascular disease, particularly in connection with sleep deprivation and the adoption of individual behaviors that increase the risk (smoking, poor diet, alcohol consumption, smoking and low physical activity). However sleep education is not integrated in a personalized way into the prevention advice provided by occupational health services.\n\nTherefore, this study aims to investigate the effects of a 6-month sleep education program conducted by occupational health nursing staff, on the sleep duration of healthcare workers newly exposed to alternating 12-hour day and night shifts.",[28],[439,440,441],"Sleep educational program","Alternating 12-hour","day and night shift","2026-03-11",{"date":444,"type":43},"2026-03-13",{"date":301,"type":22},{"date":447,"type":22},"2030-06-01",{"name":449,"class":81},"Centre Hospitalier Universitaire de Saint Etienne",3,{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":16,"sex":457,"minAge":18,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":4},"100603284","examining-the-effects-of-reformer-pilates-exercises-on-physical-fitness-and-cognitive-functions-in-healthy-individuals-100603284","NCT07134517","Examining the Effects of Reformer Pilates Exercises on Physical Fitness and Cognitive Functions in Healthy Individuals","Inclusion Criteria:\n\n* Individuals who do not have a regular exercise habit,\n* Are between the ages of 18 and 50,\n* And are inactive according to the International Physical Activity Questionnaire Short Form assessment (less than 600 MET min).\n\nExclusion Criteria:\n\n* Individuals with a history of serious musculoskeletal or neurological disease,\n* Receiving psychological support,\n* Taking regular medication,\n* With metabolic disease,\n* Describing chronic pain anywhere in their body,\n* Or with communication problems.","FEMALE","50 Years",{"count":460,"type":22},42,[137],"Pilates is an exercise method that aims to increase body awareness and improve physical fitness through controlled movements based on mind-body integration. Reformer Pilates strengthens the mind-body connection while increasing core muscle activation through equipment-assisted exercises. It is known that regular exercise has positive effects on cognitive functions through its neuroprotective and neuroplastic effects. However, the effects of Reformer Pilates on these functions have been studied in only a limited number of studies, particularly in healthy middle-aged individuals. The aim of this project proposal is to investigate the effectiveness of Reformer Pilates exercises on physical fitness and cognitive functions in healthy individuals. In this study, the effects of reformer Pilates on physical fitness and cognitive functions will be examined in healthy individuals aged 18-50. The intervention group will perform reformer Pilates twice a week for 8 weeks, while the control group will not participate in any physical activity. Body mass index, waist-to-height ratio, waist-to-hip ratio, cognitive reserve, cognitive functions, reaction time, physical fitness, grip strength, and general health status will be assessed at baseline and after 8 weeks. Cognitive functions will be assessed using the cognitive reserve index, and cognitive functions will be assessed using the Stroop test-anchor form and the tracking test. Stroop test-anchor form and tracking test; reaction time will be measured using a wireless system consisting of a laser LED light emitter and a central hand control unit; physical fitness will be assessed using The Senior Fitness Test; grip strength will be measured using a hand dynamometer; and general health status will be assessed using the General Health Questionnaire-12. Data analysis will be performed using SPSS version 25.0. For comparing pre- and post-treatment outcome measures within the group, analysis will be conducted using the t-test for dependent samples (if normally distributed) or the Wilcoxon signed-rank test (if not normally distributed). Effect size will be calculated to determine the impact of the exercise program. P\\\u003C0.05 will be considered statistically significant.",[28],[465,466,467],"Pilates","cognitive function","physical fitness","2025-08-19",{"date":470,"type":43},"2025-08-21",{"date":472,"type":22},"2025-09-01",{"date":474,"type":22},"2026-03-01",{"name":476,"class":81},"Inonu University",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":16,"sex":160,"minAge":483,"maxAge":18,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":492,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":51},"100594254","effects-of-integrative-neuromuscular-traning-on-physical-fitness-and-dribbling-performance-among-high-school-male-football-players-in-shandong-china-100594254","NCT07017049","Effects of Integrative Neuromuscular Traning on Physical Fitness and Dribbling Performance Among High School Male Football Players in Shandong, China","Inclusion Criteria:\n\n1. Male high school football players aged between 16 to 18 years\n2. Regular participation in football training without prior structured neuromuscular warm-up training experience within the last 12 months\n3. Physically healthy and capable of performing all required tests\n4. Voluntary consent to participate in all assessments and training sessions\n5. Clear understanding of the objectives and procedures of the study\n\nExclusion Criteria:\n\n1. History of significant musculoskeletal injuries (e.g., knee, ankle, or hip injuries) within the previous year\n2. Presence of current health conditions or medication use that might interfere with physical performance or muscular activity\n3. Any neurological disorders or chronic health issues that could impact participation in training or assessment\n4. Previous experience with structured neuromuscular warm-up training within the last year\n5. Uncertainty regarding the ability to consistently attend and complete the training due to personal or external factors","16 Years",{"count":485,"type":22},70,[137],"This study investigates the effects of a 12-week Integrative Neuromuscular Training (INT) program on physical fitness, balance, and dribbling skills in male high school soccer players in Shandong, China. INT, which combines strength, agility, balance, core stability, and proprioception, has been shown internationally to enhance athletic performance and prevent injuries among youth athletes. While widely applied in sports like basketball, volleyball, and swimming abroad, research on INT in Chinese male soccer players remains limited.\n\nA total of 60 male soccer players (aged 16-18) with at least two years of training experience will be recruited from two high schools in Jinan and divided equally into experimental and control groups. The experimental group will undergo INT three times per week for 12 weeks, while the control group will continue regular soccer training. The study will measure changes in strength, speed, endurance, flexibility, static and dynamic balance, and dribbling performance. Data collection spans 16 weeks, including pre-tests, intervention, and post-tests. Statistical analysis will be conducted using SPSS 26.0, employing descriptive statistics, GEE models, and repeated measures ANOVA. This research aims to provide scientific evidence for the use of INT in youth soccer training in China.",[489,28,490,491],"Adolescent","Physical Fitness and Technical Skills","Football Players",[493,494,495,467,496],"integrative neuromuscular training","football players","adolescent","drilling","2025-06-03",{"date":499,"type":43},"2025-06-12",{"date":501,"type":22},"2025-06-20",{"date":503,"type":22},"2025-10-20",{"name":505,"class":81},"Xinrui Zhang"]